Ecnoglutide
vs Retatrutide.
Compare ecnoglutide and retatrutide by single versus triple agonism, China approval, Phase 3 evidence, trial duration, safety, and FDA status.
What is the difference?
Ecnoglutide and retatrutide are separate peptide programs with no randomized head-to-head trial. Ecnoglutide is a once-weekly cAMP-biased GLP-1 receptor agonist with China approvals for chronic weight management and type 2 diabetes. Retatrutide is an investigational once-weekly GIP, GLP-1, and glucagon triple agonist with Phase 3 results but no marketing approval. Neither is FDA approved. Ecnoglutide's China approval does not make it globally available, and retatrutide's larger separate-trial headline cannot establish superiority over the approved Chinese ecnoglutide product.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Ecnoglutide
Approved in China for type 2 diabetes and chronic weight management; not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 15 matched NCT records
- Sponsor
- Sciwind Biosciences; Pfizer commercialization partner in Mainland China
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
Ecnoglutide vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between Ecnoglutide and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Ecnoglutide
cAMP-signalling-biased GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; indication-expansion studies continue
- Status
- Approved in China for type 2 diabetes and chronic weight management; not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 3
- Results posted
- 0
- Recruiting site observations
- 3
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Ecnoglutide
cAMP-signalling-biased GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; indication-expansion studies continue
- Status
- Approved in China for type 2 diabetes and chronic weight management; not FDA approved
- Featured trial anchors
- NCT05813795 · NCT05680155 · NCT05680129
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
Searchers often place a commercially authorized single-receptor product beside a still-investigational triple agonist and assume receptor count or the largest percentage answers the comparison. The current evidence can compare molecular strategy, development maturity, jurisdiction-specific approval, population, duration, estimand, and safety reporting. It cannot determine a winner because SLIMMER and TRIUMPH-1 were independent Phase 3 programs with no shared randomization.
| Field | Ecnoglutide | Retatrutide | How to interpret it |
|---|---|---|---|
| Receptor strategy | cAMP-biased GLP-1 receptor agonist | GIP, GLP-1, and glucagon receptor triple agonist | More receptor targets do not automatically mean better efficacy, tolerability, durability, or benefit-risk for a patient. |
| Evidence anchor | 15.4% mean change at 48 weeks in SLIMMER's 2.4 mg group | 28.3% efficacy-estimand mean change at 80 weeks in TRIUMPH-1's 12 mg group | Different trials, durations, populations, and estimands make direct subtraction or per-week ranking invalid. |
| Regulatory position | Approved for two indications in China; not FDA approved | Investigational Phase 3 program; not FDA approved | Clinical maturity and country-specific authorization answer different questions and must remain clearly labelled. |
| Current product record | A defined Chinese regulated injection exists | No approved commercial product exists | Neither fact authenticates a same-name online vial, supplier, imported presentation, clinic service, or research product. |
| Comparative evidence | No trial randomized participants against retatrutide | No trial randomized participants against ecnoglutide | Without a common protocol, comparative effectiveness, safety, adherence, and preference remain unresolved. |
Why the headline numbers do not name a winner.
Ecnoglutide's SLIMMER week-48 analysis reported 15.4% mean change at 2.4 mg under the treatment-policy estimand and a 15.1% placebo-adjusted difference in Chinese adults without diabetes. Retatrutide's TRIUMPH-1 report described 28.3% mean change at 80 weeks with 12 mg under an efficacy estimand and 25.0% under a treatment-regimen estimand. Population, duration, receptor design, dose escalation, placebo response, analysis, adherence, and missing-data handling differ. The numerical gap is not a direct treatment effect.
Keep the comparison honest.
- 01
Keep ecnoglutide's China product approval separate from FDA status and from any claim about availability or seller authority in another country.
- 02
Never divide the 48-week and 80-week percentages into weekly rates or use receptor count to fill the missing head-to-head evidence.
- 03
Treat online retatrutide as unapproved and require an exact China product and seller match before describing ecnoglutide as authorized supply.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →